Health

'Pharmacy of the world' is in peril

In the past decade, India’s import of Active Pharmaceuticals Ingredients and advanced intermediates used to manufacture formulations has grown rapidly

 
By Dinesh C Sharma
Last Updated: Monday 29 January 2018 | 12:07:04 PM
India has neglected its public sector drug manufacturers which have all closed down. Credit: Derek Gavey/Flickr
India has neglected its public sector drug manufacturers which have all closed down. Credit: Derek Gavey/Flickr India has neglected its public sector drug manufacturers which have all closed down. Credit: Derek Gavey/Flickr

Over the years, India has earned the sobriquet of the ‘pharmacy of the world’ for being a leading supplier of affordable drugs to many countries. But we could soon lose this tag as the Indian drug industry is increasingly becoming dependent on China for the supply of bulk drugs and intermediaries, a new study has warned.

In the past decade, India’s import of Active Pharmaceuticals Ingredients (APIs) and advanced intermediates – which are used for manufacturing formulations - has grown rapidly. India now depends on China fully for these ingredients to make not only advanced drugs but also essential medicines such as paracetamol, metformin, aspirin and a range of antibiotics such as ciprofloxacin and amoxicillin.

In 2016, India imported about 272 million kilograms of APIs and intermediates valued at 2.8 billion USD with 70 per cent coming from China. For several categories of drugs, almost all raw materials comes from China. For instance, the entire requirement of 6,000 tonnes of Pen G – an essential chemical used for manufacturing several antibiotics – is imported from China.

“While India today is preferred low-cost producer and exporter of simpler off-patent formulations, but the road taken is ‘hollowing out’ manufacturing and hampering the productive and competitive thrust of domestic firms,” points out the study conducted by the Institute for Studies in Industrial Development (ISID), New Delhi.

‘Hollowing out’ refers to deterioration of a country’s manufacturing sector when producers move important activities of manufacturing to low-cost facilities overseas or reconfigure facilities for foreign markets.

“With growing reliance of domestic firms on imports of APIs from China and rapidly evolving new patterns of outsourcing and contracting for local manufacture of formulations, we need to explore new processes of upgrading of pharmaceutical manufacturing with all relevant stakeholders - government, industry, regulators and civil society,” said Dinesh Abrol, who led the study.

The study has identified key reasons for India increasingly losing out in the drug market, and the reasons why China is succeeding. “We focused too much on cost advantage while neglecting other aspects of competitiveness. While China’s growth is led by state-owned enterprises and very strong R&D-industry interaction, India has neglected its public sector drug manufacturers which have all closed down. If we want to ensure health security of Indian people, revival of R&D and public sector API manufacturers is necessary,” Abrol explained.

Industry experts and civil society representatives, who spoke at the workshop, echoed similar sentiments. “Public sector R&D bodies like the Council of Scientific and Industrial Research (CSIR), Department of Biotechnology (DBT) contributed to the development of API capability in India, like a hub-and-spoke. Now the hub has moved to China,” said Srinivas Lanka, an industry expert.

“The fall of the hub and spoke model with neither large pharma nor CSIR labs or universities focused to develop technologies for small and medium scale enterprises, leading manufacturers have moved into formulation manufacturing, patent litigation etc. The focus on core complex chemistry has weakened due to long gestation period and high capital costs,” he added.

Being a science-based industry, the drug sector needed help from the R&D sector, said Dilip G Shah, secretary general of Indian Pharmaceutical Alliance. For instance, he said, the government should facilitate industry to work with CSIR labs for process and yield improvement. “As a country, we have become very vulnerable. You don’t need missiles and tanks to cripple us. Stopping supplies of bulk drugs will do,” warned V V Krishna Reddy, president of the Bulk Drug Manufacturers Association.

The research team included Dinesh Abrol and Rollins John (ISID); Amitava Ghosh (Jan Swasthya Abhiyan), T Kameshwar Rao and Sumanta Choudhury. The study was funded by the Indian Council of Social Science Research.

(India Science Wire)

@dineshcsharma

Subscribe to Weekly Newsletter :

Related Story:

'India’s drug dependence on China not good for its health sector'

Drug trials in India killed 2,031 persons

Drug companies are buying doctors – for as little as a $16 meal

IEP Resources:

Guidelines for the examination of patent applications relating to pharmaceuticals

Trans-Pacific trade pact triggers fears over drug prices

Regulatory process for import and export of drugs in India

Indian generic drugs debate heats up

We are a voice to you; you have been a support to us. Together we build journalism that is independent, credible and fearless. You can further help us by making a donation. This will mean a lot for our ability to bring you news, perspectives and analysis from the ground so that we can make change together.

Comments are moderated and will be published only after the site moderator’s approval. Please use a genuine email ID and provide your name. Selected comments may also be used in the ‘Letters’ section of the Down To Earth print edition.